Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Short term Debt (2020 - 2023)

GeneDx Holdings has reported Short term Debt over the past 4 years, most recently at $4.3 million for Q1 2023.

  • Quarterly results put Short term Debt at $4.3 million for Q1 2023, up 33.3% from a year ago — trailing twelve months through Mar 2023 was $4.3 million (up 33.3% YoY), and the annual figure for FY2022 was $3.6 million, up 36.98%.
  • Short term Debt for Q1 2023 was $4.3 million at GeneDx Holdings, up from $3.6 million in the prior quarter.
  • Over the last five years, Short term Debt for WGSWW hit a ceiling of $4.3 million in Q1 2023 and a floor of $797000.0 in Q1 2021.
  • Median Short term Debt over the past 4 years was $2.1 million (2022), compared with a mean of $2.3 million.
  • Peak annual rise in Short term Debt hit 306.15% in 2022, while the deepest fall reached 28.28% in 2022.
  • GeneDx Holdings' Short term Debt stood at $1.4 million in 2020, then surged by 84.07% to $2.6 million in 2021, then surged by 36.98% to $3.6 million in 2022, then increased by 20.09% to $4.3 million in 2023.
  • The last three reported values for Short term Debt were $4.3 million (Q1 2023), $3.6 million (Q4 2022), and $1.8 million (Q3 2022) per Business Quant data.